H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ETON stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including the potential launch of Eton Pharmaceuticals’ ET-600, which is expected to occur in the first quarter of 2026. The FDA has accepted the new drug application for ET-600, an oral liquid formulation of desmopressin, and assigned a PDUFA date of February 25, 2026. This formulation would be the only FDA-approved oral liquid version available, addressing a significant need in the pediatric population currently using less optimal treatments.
Ramakanth also highlights the company’s strong track record in commercial execution and its existing network of pediatric endocrinologists, which is anticipated to facilitate a smooth and rapid adoption of ET-600 upon approval. Additionally, Eton’s strategic goal of expanding its commercial portfolio to ten products by early 2026, along with a conservative revenue projection for ET-600, supports the Buy rating. The valuation analysis using a risk-adjusted net present value approach further reinforces the price target of $35 per share, despite potential risks such as clinical, commercial, and competitive challenges.
According to TipRanks, Ramakanth is a 3-star analyst with an average return of 3.2% and a 38.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, Eton Pharmaceuticals, and ALX Oncology Holdings.